Palisade Bio Ownership | Who Owns Palisade Bio?
Palisade Bio Ownership Summary
Palisade Bio is owned by 39.15% institutional investors, 0.03% insiders, and 60.82% retail investors. Vanguard group is the largest institutional shareholder, holding 28.31% of PALI shares. Franklin Biotechnology Discv A(acc)USD is the top mutual fund, with 2.19% of its assets in Palisade Bio shares.
PALI Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Palisade Bio | 39.15% | 0.03% | 60.82% |
| Sector | Healthcare Stocks | 35.74% | 11.83% | 52.43% |
| Industry | Biotech Stocks | 36.05% | 11.82% | 52.13% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Vanguard group | 2.12M | 28.31% | $4.97M |
| B group | 11.41M | 20.50% | $19.97M |
| Janus henderson group | 10.69M | 19.20% | $18.76M |
| Octagon capital advisors lp | 10.28M | 18.46% | $17.98M |
| Perceptive advisors | 8.93M | 16.04% | $15.62M |
| Ameriprise financial | 8.71M | 15.65% | $15.24M |
| Commodore capital lp | 7.18M | 12.90% | $12.57M |
| Ra capital management | 7.12M | 12.80% | $12.47M |
| Franklin resources | 5.79M | 10.39% | $10.12M |
| Goldman sachs group | 5.37M | 9.65% | $9.40M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| B group | 11.41M | 14.81% | $19.97M |
| Octagon capital advisors lp | 10.28M | 1.99% | $17.98M |
| Great point partners | 3.41M | 1.37% | $5.96M |
| Propel bio management | 1.11M | 1.26% | $2.00M |
| Boxer capital management | 4.80M | 1.10% | $8.40M |
| Highvista strategies | 2.02M | 0.98% | $3.53M |
| Artia global partners lp | 1.99M | 0.77% | $3.49M |
| Commodore capital lp | 7.18M | 0.73% | $12.57M |
| Platinum investment management | 1.23M | 0.54% | $2.15M |
| Exome asset management | 600.00K | 0.54% | $1.05M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| B group | 11.41M | 14.81% | 6.91M |
| Goldman sachs group | 5.37M | 0.00% | 4.82M |
| Great point partners | 3.41M | 1.37% | 3.41M |
| Federated hermes | 3.14M | 0.01% | 3.14M |
| Balyasny asset management | 3.27M | 0.01% | 2.95M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Point72 asset management | 411.77K | 0.00% | -10.08M |
| Commodore capital lp | 7.18M | 0.73% | -4.26M |
| Stempoint capital lp | - | - | -4.19M |
| Perceptive advisors | 8.93M | 0.31% | -3.12M |
| Vivo capital | - | - | -2.29M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Great point partners | 3.41M | 1.37% | 3.41M | $5.96M |
| Federated hermes | 3.14M | 0.01% | 3.14M | $5.49M |
| Wellington management group llp | 2.90M | 0.00% | 2.90M | $5.08M |
| Marshall wace, llp | 2.75M | 0.00% | 2.75M | $4.82M |
| Vestal point capital, lp | 2.50M | 0.12% | 2.50M | $4.38M |
Sold Out
| Holder | Change |
|---|---|
| Fmr | -10.00 |
| Wells fargo & company/mn | -21.00 |
| Federation des caisses desjardins du quebec | -100.00 |
| Avion wealth | -500.00 |
| Virtu financial | -11.87K |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 43 | -50.00% | 21,793,656 | -83.96% | 39 | 0.00% | 28 | -65.85% | 12 | 1100.00% |
| Dec 31, 2025 | 35 | 191.67% | 20,638,757 | 17157.64% | 276 | 10785.35% | 33 | 266.67% | - | -100.00% |
| Sep 30, 2025 | 12 | 9.09% | 119,592 | 41.34% | 1 | 51.44% | 9 | 80.00% | 1 | -66.67% |
| Jun 30, 2025 | 11 | - | 84,610 | -67.53% | 1 | 5.97% | 5 | -37.50% | 3 | 200.00% |
| Mar 31, 2025 | 11 | 22.22% | 260,593 | 30.80% | 5 | 2.75% | 8 | 33.33% | 1 | - |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| Franklin Biotechnology Discv A(acc)USD | 3.66M | 2.19% | - |
| Federated Hermes Kaufmann Small Cap A | 3.14M | 1.87% | 3.14M |
| Federated Hermes Kaufmann Small Cap Grow | 3.14M | 1.87% | 3.14M |
| Biotech Growth Ord | 2.33M | 1.39% | - |
| Franklin Biotechnology Discovery A | 2.12M | 1.26% | - |
| Vanguard Institutional Extnd Mkt Idx Tr | 1.43M | 0.85% | 442.00 |
| abrdn Life Sciences Investors | 1.11M | 0.66% | 444.50K |
| Fidelity Extended Market Index | 690.58K | 0.41% | 12.41K |
| Truvalue Glb Phrmctl Blgcl Eq (QDII) A | 548.12K | 0.33% | 548.12K |
| Simplify Propel Opportunities ETF | 532.52K | 0.32% | - |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Feb 12, 2026 | Jones Mitchell Lawrence | Chief Medical Officer | Sell | $3.48K |
| Feb 12, 2026 | Finley John David | CEO, CFO | Sell | $6.82K |
| Jan 16, 2026 | Williams Donald Allen | - | Buy | $8.36K |
| Jan 09, 2026 | Williams Donald Allen | - | Buy | $9.40K |
| May 28, 2024 | Williams Donald Allen | - | Buy | $4.86K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q2 | - | - |
| 2026 Q1 | 2 | 2 |
| 2025 Q4 | - | - |
| 2025 Q3 | - | - |
| 2025 Q1 | - | - |
PALI Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools